Spero Therapeutics, Inc. (SPRO) Form S-3 — Aug 28, 2026
Spero Therapeutics filed a $300 million shelf registration statement covering debt securities, common stock, preferred stock, depositary shares, subscription rights, units and warrants, to be offered from time to time via future prospectus supplements. The filing also includes a sales agreement prospectus for up to $100 million of common stock to be sold at-the-market through Jefferies LLC as agent, with Jefferies earning up to 3.0% of gross proceeds; Spero's last reported sale price was $1.21 per share on August 27, 2026.
Key figures
- Gross Proceeds
- up to $100,000,000 under the ATM sales agreement (included within a $300,000,000 total shelf)
- Offering Price
- at-the-market pricing; last reported sale price $1.21 per share on August 27, 2026
- Shares Outstanding
- 58146910
- Atm Capacity Usd
- 100000000
- Rsu Shares Vesting
- 4173783
- Shelf Capacity Usd
- 300000000
- Jefferies Commission
- up to 3.0% of aggregate gross proceeds
- Assumed Atm Shares Sold
- 82644628
- Last Reported Sale Price
- 1.21
- Authorized Common Shares
- 240000000
- Stock Options Outstanding
- 3,569,033 shares at a weighted average exercise price of $7.20
- Authorized Preferred Shares
- 10000000
- Pro Forma Shares Outstanding
- 140791538
- Dilution To New Purchasers Per Share
- 0.21
- Adjusted Net Tangible Book Value Post Offering
- approximately $141.1 million, or approximately $1.00 per share
Price after filing
Close on the filing date to close N calendar days later (from $1.20). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.